Quest Diagnostics will soon begin offering a new blood-based in-vitro diagnostic test for Alzheimer’s. The disease affects nearly 7 million Americans. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma ...

Quest Diagnostics unveiled a first-to-market blood test available for consumer purchase that detects and measures the level of per- and polyfluorinated alkyl substances (PFAS), a potentially harmful ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. Developed by Fujirebio, the Lumipulse G test measures ...

"Quest's AD-Detect suite of advanced diagnostics has grown to include a range of validated blood-based biomarkers, giving providers options for personalizing testing for the individual patient," said ...

Please provide your email address to receive an email when new articles are posted on . Labcorp and Quest Diagnostics have both announced the availability of blood-based biomarker testing for ...

SECAUCUS, N.J., Oct. 27, 2025 /PRNewswire/ -- Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer's disease pathology in symptomatic patients, supporting ...

MADISON - Wisconsinites worried about "forever chemicals" now have a new way to test for levels in their blood. Quest Diagnostics released a new test for about $300 that will survey blood for nine ...

SECAUCUS, N.J., June 10, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a collaboration with The University of Texas MD ...

Quest Diagnostics may be the preferred lab your health insurance, doctors, or specialists use for blood work or other samples. We’re reviewing its sub-brand Quest Health, from which you can order your ...

Lab tests offer insights for individuals who may experience inadequate intake of essential nutrients due to dietary restrictions, certain prescription medications, or chronic health conditions ...

In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and ...